［1］Nixon JE.Avascular necrosis of bone:A review［J］.JR Soc Med,1983,76(8):681-692.
［2］Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws：A growing epidemic［J］.Oral Maxillofacial Surg,2003(61)：1115-1118.
［3］Sambrook P,Olver I,Goss A.Bisphosphonates and osteonecrosis of the jaw［J］.Aust Fam Physician,2006,35(10):801-803.
［4］Sambrook PN.Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw［J］.Nat Clin Pract Rheumatol,2009,5(1):6-7.
［5］American Association of Oral and Maxillofacial Surgeons.Position paper on bisphosphonate-related osteonecrosis of the jaws［J］.J Oral Maxillofac Surg,2007,65(3):369-376.
［6］Khan AA,Sandor GK,Dore E,et al.Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw［J］.J Rheumatol,2008,35(7):1391-1397.
［7］Ruggiero SL,Dodson TB,Assael LA,et al.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update［J］.Aust Endod J,2009,35(3):119-130.
［8］Ruggiero SL,Dodson TB,Fantasia J,et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update［J］.J Oral Maxillofac Surg,2014,72(10):1938-1956.
［9］Marx RE.Bisphosphonate-induced osteonecrosis of the jaws:A challenge,a responsibility,and an opportunity［J］.Int J Periodontics Restorative Dent,2008,28(1):5-6.
［10］Kelleher FC,McKenna M,Collins C,et al.Bisphosphonate induced osteonecrosis of the jaws:Unravelling uncertainty in disease causality［J］.Acta Oncol,2007,46(5):702-704.
［11］Migliorati CA,Casiglia J,Epstein J,et al.Managing the care of patients with bisphosphonate-associated osteonecrosis:An American Academy of Oral Medicine position paper［J］.J Am Dent Assoc,2005,136(12):1658-1668.
［12］Khosla S,Burr D,Cauley J,et al.Bisphosphonate-associated osteonecrosis of the jaw:Report of a task force of the American Society for Bone and Mineral Research［J］.J Bone Miner Res,2007,22(10):1479-1491.
［13］Wimalawansa SJ.Bisphosphonate-associated osteomyelitis of the jaw:Guidelines for practicing clinicians［J］.Endocr Pract,2008,14(9):1150-1168.
［14］Yamazaki T,Takahashi K,Bessho K.Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw:Focus on Risk,Prevention and Treatment［J］.Rev Recent Clin Trials,2014,9(1):37-52.
［15］Hellstein JW,Adler RA,Edwards B,et al.Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis:Executive summary of recommendations from the American Dental Association Council on Scientific Affairs［J］.J Am Dent Assoc,2011,142(11):1243-1251.
［16］Wessel JH,Dodson TB,Zavras AI.Zoledronate,smoking,and obesity are strong risk factors for osteonecrosis of the jaw:A case-control study［J］.J Oral Maxillofac Surg,2008,66(4):625- 631.
［17］Ruggiero S,Gralow J,Marx RE,et al.Practical guidelines for the prevention,diagnosis,and treatment of osteonecrosis of the jaw in patients with cancer［J］.J Oncol Pract,2006,2(1):7-14.
［18］Glick M.Closing in on the Puzzle of ONJ［J］.J Am Dent Assoc,2008,139(1):12,14-15.
［19］Pelaz A,Junquera L,Gallego L,et al.Epidemiology,pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw.A re-trospective study of 70 cases［J］.Acta Otorrinolarin-gol Esp,2015,66(3):139-147.
［20］Günaldi M,Afsar CU,Duman BB,et al.Effect of the cumulative dose of zoledronic acid on the pathoge-nesis of osteonecrosis of the jaws［J］.Oncol Lett,2015,10(1):439-442.
［21］ Kos M.Incidence and risk predictors for osteone-crosis of the jaw in cancer patients treated with in-travenous bisphosphonates［J］.Arch Med Sci,2015,11(2):319-324.
［22］ Nisi M,La Ferla F,Karapetsa D,et al.Risk factorsin fluencing BRONJ staging in patients receiving intravenous bispho sphonates:A multivariate analysis［J］.Int J Oral Maxillofacsurg,2015,44(5):586-591.
［23］Diniz-Freitas M,Fernández-Feijoo J,Diz P,et al.Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy:A case report［J］.Journal of Clinical Periodntology,2018,45(5):570-577.
［24］H Antov.Medication-related osteonecrosis:Patients with a hidden risk of MRONJ［J］.British Dental Journal,2019,226(86):1476-5373.
［25］Hasegawa T,Hayashida S,Kondo E,et al.Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients:A multicenter retrospective study［J］.Osteoporosis International,2019,30(1):231-239.
［26］ Sakaguchi O,Kokuryo S,Tsurushima H,et al.Lipopolysaccharide aggravates bisphosphonate-induced osteonecrosis in rats ［J］.Int J Oral Maxillofac Surg,2015(4):528-534.
［27］Landesberg R,Taxel P.Osteonecrosis of the jaw and rheumatoid arthritis.Is it the disease or the drugs［J］.J Rheumatol,2013,40(6):749-751.
［28］Schiodt M,Wexell CL,Herlofson BB,et al.Existing data sources for clinical epidemiology:Scandinavian Cohort for osteonecrosis of the jaw-work in progress and challenges［J］.Clin Epidemiol,2015(7):107-116.
［29］Ristow O,Gerngro C,Schwaiger M,et al.Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis［J］.J Oral Maxillofac Surg,2014,72(5):903-910.
［30］Aljohani S,Fliefel R,Ihbe J,et al.What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients:A systematic review［J］.J Craniomaxillofac Surg,2017,45(9)：1493-1502.
［31］Wang Qi-Zhang,Liu Ji-Yuan,Pan Jian,et al.Progress on medication-related osteonecrosis of the jaw［J］.West China Journal of Stomatology,2018,36(5):568-572.
［32］M Almahndr,D Kashtwari,S Barghan,et al.Mandibular osteonecrosis/osteomylitis in A patient with crohn disease［J］.Oral Surgery,Oral Medicine,Oral Pathology and Oral Radiology,2019,127(33):2212-4403.
［33］Saad F,Brown JE,Van Poznak C,et al.Incidence，risk factors， and outcomes of osteonecrosis of the jaw:Integrated analysis from three blinded active- controlled phase III trials in cancer patients with bone metastases ［J］.Ann Oncol,2012,23(5)：1341-1347.
［34］Marx RE,Sawatari Y,Fortin M,et al.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws:Risk factors,recognition,prevention,and treatment［J］.J Oral Maxillofac Surg,2005,63(11):1567-1575.
［35］Marx RE.Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws.History,Etiology,Prevention,and Treatment［J］.2nd Ed，Chicago:Quintessence Pub Co,2011.
［36］Neviaser AS,Lane JM,Lenart BA,et al.Low-energy femoral shaft fractures associated with alendronate use［J］.J Orthop Trauma,2008,22(5):346-350.
［37］Schiodt M,Reibel J,Oturai P,et al.Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws:A retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system［J］.Oral Surg Oral Med Oral Pathol Oral Radiol,2014,117(2):204-213.
［38］Fedele S,Bedogni G,Scoletta M,et al.Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed［J］.Br J Oral Maxillofac Surg,2015,53(1):13-17.
［39］ HE Jie,QIU Wei-liu,et al.Bisphosphonate and osteonecrosis of the jaw［J］.Chinese Journal of Oral and Maxillofacial Surgery，2010,8(4): 370-375．
［40］Ruggiero SL,Fantasia J,Carlson E.Bisphosphonate-related Osteonecrosis of the jaw:Background and guidelines for diagnosis,staging and management［J］.Oral Surg Oral Med Oral Pathol Oral Radio Endod,2006（102）:433-441.
［41］Williams WB，O' Ryan F.Management of medication-related osteonecrosis of the jaw［J］.Oral Maxillofac Surg ClinNorth Am，2015，27(4)：517-525.
［42］Lazarovici TS,Yahalom R,Taicher S,et al.Bisphosphonate related osteonecrosis of the jaw associated with dental implants［J］.Oral Maxillofac Surg,2010(68):790-796.
［43］Moretti F，Pelliccioni GA，Montebugnoli L，et al.A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosph-onate- associated osteonecrosis of the jaws［J］.Oral Surg Oral Med Oral Pathol Oral Radiol Endod，2011，112(6)：777-782.
［44］Wang Q,Liu J,Guo T,et al.Epidermal growth factor reverses the inhibitory effects of the bisphosphonate,zoledronic acid,on human oral keratinocytes and human vascular endothelial cells in vitro via the epidermal growth factor receptor(EGFR)/Akt/Phosphoinositide 3-Kinase (PI3K) signaling pathway.［J］.Medical science monitor,2019（25）:700-710.
［45］Z Rahman,S Nayani,H Anstey,et al.A survey evaluating the awareness of MRONJ within the Birmingham GMP community［J］.Oral Surgery,2019,12(1):22-29.
［46］Panya S,Fliefel R,Probst F,et al.Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ)［J］.Journal of Cranio-maxillofacial Surgery,2017,45(3):357-363.
［47］Alrmali,Abdusalam.A minimally invasive protocol for the prevention and management of medication-related osteonecrosis of the jaw［J］.Clinical Oral Implants Research,2018,29(17):465.
［48］Schiodt M,Reibel J,Oturai P,et al.Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws:A retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system［J］.Oral Surg Oral Med Oral Pathol Oral Radiol,2014,117(2):204-213.
［49］Wilde F， Heufelder M， Winter K， et al.The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw［J］.Oral Surg Oral Med Oral Pathol Oral Radiol Endod，2011，111(2)：153-163.
［50］Morten Schiodt,Jesper Reibel,Peter Oturai,et al.Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database［J］.Therapeutics and Clinical Risk Management，2019(15)：1176-6336.
［51］Mong-Hun Kang，Dong-Keon Lee.Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw［J］.Journal of the Korean Association of Oral and Maxillofacial Surgeons,2018,44(5):225-231.